Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this opens up. Furthermore, he highlights the future potential of the biosimilar market and the company´s plans to design their own innovative product.
Mabion´s own product, MabionCD20, completed clinical trials this year and a historic partnership was set-up with Mylan for the EU and the Baltic states. How would you describe this experience thus far?
"We believe Mabion can remain competitive in the long term as Poland offers a great opportunity to generate good profit margins on products."
